Immunocore Holdings plc (NASDAQ:IMCR) Receives Consensus Rating of “Moderate Buy” from Analysts

Shares of Immunocore Holdings plc (NASDAQ:IMCR) have been assigned a consensus rating of “Moderate Buy” from the thirteen research firms that are presently covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, four have assigned a hold recommendation and eight have given a buy recommendation to the company. The average 1 year target price among brokers that have issued ratings on the stock in the last year is $65.64.

Several analysts have recently weighed in on IMCR shares. Needham & Company LLC decreased their target price on shares of Immunocore from $78.00 to $71.00 and set a “buy” rating on the stock in a research report on Thursday, November 7th. HC Wainwright reaffirmed a “buy” rating and set a $100.00 price objective on shares of Immunocore in a report on Thursday, October 24th. Guggenheim lowered Immunocore from a “buy” rating to a “neutral” rating in a research note on Monday, October 7th. Morgan Stanley restated an “equal weight” rating and set a $35.00 target price (down previously from $74.00) on shares of Immunocore in a research report on Friday, December 13th. Finally, Mizuho cut Immunocore from an “outperform” rating to a “neutral” rating and lowered their price target for the company from $72.00 to $38.00 in a research report on Monday, November 11th.

Immunocore Stock Down 1.9 %

IMCR stock opened at $30.23 on Friday. Immunocore has a twelve month low of $27.69 and a twelve month high of $76.98. The company has a quick ratio of 3.76, a current ratio of 3.78 and a debt-to-equity ratio of 1.03. The company has a market cap of $1.51 billion, a PE ratio of -31.82 and a beta of 0.76. The business’s 50-day simple moving average is $31.19 and its 200 day simple moving average is $33.80.

Immunocore (NASDAQ:IMCR) last issued its earnings results on Wednesday, November 6th. The company reported $0.17 EPS for the quarter, beating analysts’ consensus estimates of ($0.33) by $0.50. Immunocore had a negative return on equity of 12.84% and a negative net margin of 15.87%. The business had revenue of $80.25 million during the quarter, compared to analyst estimates of $78.94 million. During the same period in the prior year, the company posted ($0.59) earnings per share. Immunocore’s revenue was up 23.7% on a year-over-year basis. On average, research analysts anticipate that Immunocore will post -0.94 earnings per share for the current year.

Institutional Investors Weigh In On Immunocore

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Exchange Traded Concepts LLC raised its position in shares of Immunocore by 40.4% during the third quarter. Exchange Traded Concepts LLC now owns 5,075 shares of the company’s stock worth $158,000 after acquiring an additional 1,461 shares during the last quarter. Connective Portfolio Management LLC acquired a new stake in Immunocore in the third quarter worth about $218,000. China Universal Asset Management Co. Ltd. increased its position in Immunocore by 69.7% in the third quarter. China Universal Asset Management Co. Ltd. now owns 7,433 shares of the company’s stock worth $231,000 after purchasing an additional 3,053 shares during the period. XTX Topco Ltd bought a new stake in Immunocore during the 2nd quarter worth about $303,000. Finally, GSA Capital Partners LLP acquired a new position in Immunocore during the 3rd quarter valued at about $406,000. Institutional investors and hedge funds own 84.50% of the company’s stock.

About Immunocore

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.